Literature DB >> 33554142

Optimized protocol for gene editing in adipocytes using CRISPR-Cas9 technology.

Yan Qiu1, Qiurong Ding1,2.   

Abstract

We present a detailed protocol for gene editing in adipocytes using the CRISPR-Cas technology. This protocol describes sgRNA design, preparation of lentiCRISPR-sgRNA vectors, functional validation of sgRNAs, preparation of lentiviruses, and lentiviruses transduction in adipocytes. Moreover, an optimized method of gene editing using the lentiCRISPRv2 vector expressing two sgRNAs targeting two different genes has also been described. For complete details on the use and execution of this protocol, please refer to Qiu et al. (2020).
© 2021 The Author(s).

Entities:  

Keywords:  CRISPR; Cell culture; Metabolism; Molecular biology

Mesh:

Substances:

Year:  2021        PMID: 33554142      PMCID: PMC7844572          DOI: 10.1016/j.xpro.2021.100307

Source DB:  PubMed          Journal:  STAR Protoc        ISSN: 2666-1667


Before you begin

The RNA-guided CRISPR/Cas9 (clustered regularly interspaced short palindromic repeats (CRISPR)-associated protein 9) technology has been widely used in gene editing. CRISPR/Cas9 system consists of the nuclease Cas9 and the guide RNA, which guides Cas9 to cleave DNA and produce DNA double-stranded breaks (DSBs) at a specific genomic locus. The generated DSBs can be repaired via the NHEJ (non-homologous end joining) or HDR (homology directed recombination) pathway, both of which can be adopted to mediate a desired editing outcome. This protocol describes the use of lentiCRISPR mediated gene knockout in pre-adipocytes, which can be then differentiated into mature adipocytes for functional studies. This protocol can also be applied to adipocyte cell lines.

sgRNA design and synthesis

Timing: 30 min sgRNA design. Input target genomic DNA sequence. sgRNAs can be designed using the online CRISPR Design Tool. For example, http://tools.genome-engineering.org (Ran et al., 2013), Broad Institute GPP (Sanson et al., 2018, Doench et al., 2016), Synthego (https://design.synthego.com/#/), etc. sgRNAs can also be designed manually. Obtain the gene coding sequence (CDS) from the NCBI gene database (https://www.ncbi.nlm.nih.gov) by searching the gene name in the designated assembly. Copy the CDS and import the CDS into the UCSC genome browser (http://genome.ucsc.edu) to obtain the corresponding genomic sequence. Select the most common exon among all isoforms to obtain the DNA sequence. In this protocol, we do not consider the functional difference of different isoforms, thus recommend to select the most common exon among all isoforms for sgRNA design; in case researchers are interested in functional differences between different isoforms, targeting isoform specific exon would be a better choice. Single-guide RNA (sgRNA) sequences can be manually selected by identifying the 20-bp sequence directly upstream of any 5′-NGG (protospacer adjacent motif, PAM) or downstream of any 5′-CCN. CRITICAL: It is recommended to select sgRNAs with high specificity, which can be assessed by searching in the UCSC genome browser (http://genome.ucsc.edu). Typically, design three or more sgRNAs for the first time according to the target gene coding region. Then select sgRNA with the highest editing activity for gene editing in pre-adipocytes. sgRNA synthesis. Design the sgRNA oligonucleotide primers as follows: sgRNA Forward: 5′-CACCGNNNNNNNNNNNNNNNNNNNN-3′, sgRNA Reverse: 5′-AAACNNNNNNNNNNNNNNNNNNNNC-3′. The highlighted region represents the 20-nt sgRNA sequence; the forward primer is 20-nt upstream of 5′-NGG, and the reverse primer complements the 20 highlighted nucleotides of the forward primer. Order the designed sgRNA oligonucleotides.

Key resources table

Materials and equipment

Induction medium for differentiation of brown pre-adipocytes Always prepare freshly before use. Maintenance medium for differentiation of brown pre-adipocytes Always prepare freshly before use. Preparation of PEI stock Add linear PEI (50 mg) to 50 mL sterile water in a 50-mL conical tube. Place the tube at 55°C in a water bath and vortex every 10 min until PEI is completely dissolved. The PEI solution is cooled to room temperature (∼25°C), filter sterilized using a 0.22-μm vacuum filter and stored at 4°C for up to 5 months or longer. Preparation of LB buffer LB buffer is autoclaved at 121°C for 15 min. Add antibiotics after the LB buffer is cooled adequately. The LB buffer can be stored at room temperature (∼25°C) for up to 1 month or longer. The use of antibiotics depends on the vectors that used. When culture LentiCRISPRv2-based vector, add ampicillin to the LB buffer before use. The final concentration of ampicillin is 100 μg/mL. Preparation of LB agar plates To prepare LB agar plates, add 15 g agar powder to 1 L LB buffer and autoclave for 15 min at 121°C. After adequate cooling, add antibiotics to the LB buffer, and pour into the petri dishes. Allow to solidify. The LB agar plates can be stored at 4°C for up to 45 days or longer. Preparation of 3× SDS-PAGE loading buffer The 3× SDS-PAGE loading buffer can be stored at room temperature (∼25°C) for up to 1 month or longer.

Step-by-step method details

Preparation of lentiCRISPR-sgRNA vector

Timing: 3 days sgRNA can also be delivered by retrovirus or by electroporation. If you already have the established retroviral vector, directly jump to step 6 of the sgRNA screening part for instructions on how to screening sgRNAs with high editing activity. Skip the part on lentiviruses preparation and infection (steps 4–6), if you are preparing to deliver genes via electroporation. Day 1. Part One-Preparation of sgRNA oligonucleotide inserts. Dissolve the sgRNA oligonucleotides in ddH2O and dilute to a final concentration of 10 μM. Set up the following reaction for each pair of sgRNA oligonucleotides: The KOD buffer is from the KOD-Plus-Neo kit (TOYOBO, # KOD-401). Anneal these sgRNA oligonucleotides at 95°C for 5 min, and cool the mixture to room temperature (∼25°C). Day 1. Part Two-Digestion of the lentiCRISPRv2 plasmid. This step can also be done before step 1. The lentiCRISPRv2 plasmid is obtained as a gift from Feng Zhang (Addgene plasmid #52961; RRID: Addgene_52961): Digest the lentiCRISPRv2 plasmid (1 μg) with 0.5 μL BsmBI enzyme at 55°C for 1 h. Run samples on 1% (wt/vol) agarose gel to verify the appropriately sized fragment (12,994-nt DNA fragment). Successful digestion should yield 12,994-nt and 1,879-nt DNA fragment. Day 1. Part Three-Cloning of sgRNA into the lentiCRISPRv2 vector. Set up the ligation reaction for each sgRNA as following: Incubate the ligation reaction at room temperature (∼25°C) for 2 h. Transform the ligation reaction into a Trans5α chemically competent cell. Incubate the mixture on ice for 30 min, followed by heat shock at 42°C for 30 s, and immediately re-incubate on ice for 2 min. It is recommended to transform the lentiviral plasmids in NEB Stable competent cell or One Shot StbI3 chemically competent cell (Invitrogen) to reduce potential homologous recombination. Add 100 μL LB buffer to the ligation mixture from step 3c, then incubate the mixture at 37°C for 1 h in a shaker. Add the mixture from step 3d onto an LB plate with 100 μg/mL ampicillin. Incubate the LB plate at 37°C for 12–16 h. CRITICAL: Prepare a negative control plate (ligation of BsmBI-digested lentiCRISPRv2 alone without annealed sgRNA oligo insert). Day 2: Assess the plate for colony growth. Typically, multiple colonies should grow on the lentiCRISPR-sgRNA (sgRNA inserted into lentiCRISPRv2 plasmid) plate, and the negative control plate should not have colony growth. Select two or three colonies from the lentiCRISPR-sgRNA plate to confirm the insertion of sgRNA into lentiCRISPRv2 vector. Grow each single colony in 3 mL LB buffer with 100 μg/mL ampicillin and shake the LB buffer at 37°C for 6 h. The time for incubation is flexible. Isolate plasmid DNA from the bacterial cultures using a TIANprep Mini Plasmid Kit, according to the manufacturer’s instructions (https://www.tiangen.com/asset/imsupload/up0062501001604555834.pdf). Day 3. Verify the CRISPR vector, designated as lentiCRISPR-sgRNA1, by sequencing. Sequence each colony from the U6 promoter using the U6 primer. The 20-bp sgRNA sequence should be inserted between the U6 promoter and the remainder of the sgRNA scaffold. Further details and sequence of the lentiCRISPRv2 vector can be found at http://n2t.net/addgene:52961.

Screening sgRNAs with high editing activity

Timing: 11 days It is recommended to screen for sgRNAs with high editing activity in HEK293T cells (for gene editing in human cells) and NIH3T3 cells (for gene editing in mouse cells). Preparation of lentiCRISPR-sgRNA virus Timing: 5 days HEK293T cells culture. Culture cells in DMEM supplemented with 10% FBS at 37°C and 5% CO2. Day 1. Prepare cells for transfection. Plate HEK293T cells onto 10-cm plates in DMEM supplemented with 10% FBS 16–24 h prior to transfection. Typically, plate ∼4 × 106 cells in a 10-cm plate (∼5 × 104 cells/cm2). It is recommended to transfect the plasmid mix when cells are 80%–90% confluent. Day 2. On the day of transfection, replace the growth medium with 6–8 mL DMEM 4–6 h before transfection. Prepare polyethylenimine (PEI) transfection reagents for each 10-cm plate as following: CRITICAL: It is important to perform this step gently and carefully because HEK293T cells can be easily detached. It is also recommended to pre-coat cell culture plates with poly-L-lysine or collagen to prevent cell detachment. PEI-based transfection can be replaced with calcium phosphate or lipofection-based approaches. Mix the lentiviral plasmid with the packaging vectors (total ∼25 μg plasmid DNA), and subsequently dilute the mixture in 300 μL DMEM by pipetting up and down for a few times. Mix the PEI stock gently before use. Thereafter, add 75 μL PEI (the ratio of PEI volume (μL) to the amount of total DNA (μg) is 1:3) to 300 μL DMEM and mix gently by pipetting up and down for a few times. Add the PEI/DMEM solution (375 μL) to the diluted DNA/DMEM mixture and mix immediately by pipetting up and down for a few times or vortexing. Incubate the mixture at room temperature (∼25°C) for 15 min, and add the mixture to each plate with gentle rocking for 2 or 3 times. After 4–6 h, replace DMEM with growth medium. Days 4 and 5. Collect the virus-containing medium 48 h and 72 h after transfection. Thereafter, filter the medium with a 0.45 μm vacuum filter, and store the virus-containing medium at 4°C for immediate use. For longer term storage at −80°C, the virus-containing medium can be concentrated by centrifugation with a Beckman JA25.50 rotor (capacity for eight tubes) at 48,384 × g for 2 h at 4°C. Lentivirus can be dissolved in cold PBS or DMEM. Usually, for one 50 mL tube, it is recommended to dissolve the virus with 200 μL cold PBS or DMEM. For more detailed information about the production and purification of lentiviruses, please refer to (Tiscornia et al., 2006, Dull et al., 1998). Lentivirus can also be concentrated via polyethylene glycol (PEG)-based system (Larcombe et al., 2019). Troubleshooting 1 (Low titers of lentiviruses) Timing: 2–3 h Lentivirus titration (: Titer the concentrated lentivirus with a commercial qPCR Lentivirus Titration Kit, according to the manufacturer’s instructions (https://www.abmgood.com/pub/media/productdocument/document//l/v/lv900_datasheet_v18.pdf). Typically, the lentivirus titer of a 10-cm plate is ∼1 × 107 pfu. Lentiviruses transduction in NIH3T3 cells Timing: 6 days Day 1. Plate NIH3T3 cells in a 12-well plate 1 day before transduction. Day 2. Infect cells with lentiviruses at a MOI of ∼30 and allow lentivirus-infected cells to grow for another 2 days. Day 4. Treat cells with 3.5 μg/μL puromycin for 2 days to remove non-infected cells. Day 6. Collect cells for genomic DNA extraction. Polybrene can be added to increase transduction efficiency. CRITICAL: Do not forget to set up control groups (cells infected with lentiviruses that carry no sgRNA or express only GFP). At least include one of them as a control, and it is recommended to include both as controls. Surveyor assay to validate sgRNA function Timing: 1 day The Cas9 and sgRNA in cells can cause genomic insertion or deletion (indel) mutations, which can be detected via either the surveyor assay or sequencing. The surveyor primers can be designed via the online Primer Design Tool. For example, Primer 3.0 Web (http://primer3.ut.ee). Extract genomic DNA from different group cells using the TIANamp Genomic DNA Kit, according to the manufacturers’ instruction (https://www.tiangen.com/asset/imsupload/up0484377001604554551.pdf). Set up the PCR reaction as follows: Design PCR primers for amplification (Surveyor-F/R) of the target region with the predicted SpCas9 cut site in the center. It is recommended to design a primer pair that will produce a ∼600 bp band. Then perform PCR using the following cycling conditions: The time for extension is mainly determined by the length of DNA product and the DNA polymerase used. Run the PCR products on a 1% (wt/vol) agarose gel. Purify the PCR product using a Gel Extraction Kit, according to the manufacturers’ instruction (https://www.cwbiotech.com/uploads/websitepdf/216c4037-3eae-4ac2-b86a-762277a7adc1.pdf). Anneal the PCR products as follows: Put the mixture at 95°C for 5 min. Take equal amounts of DNA product from different lentiviruses-treated cells (lentiviruses carrying sgRNA or no sgRNA) for analysis. Digest the annealed DNA fragments with 0.5 μL T7 Endonuclease I (T7EI) enzyme at 37°C for 1 h. Run samples on a 1% (wt/vol) agarose gel. Determine the cleavage efficiency by quantifying gel bands without overexposing them. A high-efficiency sgRNA will result in obvious cleavage bands, whereas the negative controls should have no cleavage bands. Troubleshooting 4 (No obvious cleavage bands after T7 endonuclease I digestion).

Optional steps

Timing: 5 days Two sgRNAs can be cloned into one lentiCRISPRv2 vector. The lentiCRISPRv2 vector can be modified to target two different genes simultaneously. Day 1. Prepare the following reaction mixture to digest 1 μg of pUC57-MU6-gRNA plasmid DNA: Digest the pUC57-MU6-gRNA plasmid with 0.5 μL BbsI enzyme at 37°C for 2.5 h and run the product on a 1% (wt/vol) agarose gel to verify successful fragment. The pUC57-MU6-gRNA plasmid can also be digested with BbsI enzyme at 37°C for 8–12 h. Days 1–3. Clone another sgRNA into the pUC57-MU6-gRNA plasmid, which is called pUC57-sgRNA2. The protocol is identical to that in step 3. Day 3. Part One. Digest the pUC57-sgRNA2 vector with EcoRI enzyme at 37°C for 1 h. Run samples on a 1% (wt/vol) agarose gel to verify successful fragment (the 430-bp-long product), which is designated as Mouse U6-sgRNA2. Successful reactions should yield a 430-bp fragment and a 2,713-bp fragment. Day 3. Part Two. Digest the lentiCRISPR-sgRNA1 vector (from step 3) with EcoRI enzyme at 37°C for 1 h. Run samples on a 1% (wt/vol) agarose gel to verify successful fragment. Day 3. Part Three. Ligate the Mouse U6-sgRNA2 fragment from step 8c into the digested lentiCRISPR-sgRNA1 from step 8d. Set up the ligation reaction as follows: Days 3–5. All other steps are identical to step 3. It can also be achieved by delivering two sgRNAs from two separate viruses when using higher MOI for infection to simultaneously knockout two genes in one cell.

Lentiviral transfection of adipocytes

Timing: 5 days + differentiation Pre-adipocytes culture and transduction Timing: 5 days This protocol does not consider the effect of a specific gene on adipocytes differentiation. To exclude possible effect of a gene during adipocyte differentiation, we recommend the use of inducible CRISPR/Cas9 system, for example, the pCW-Cas9 (Addgene, #50661), to start gene editing after adipocyte differentiation in mature adipocytes. Infect pre-adipocytes with the inducible CRISPR/Cas9 system to introduce the Cas9 and sgRNA cassettes to cells, and induce the Cas9 expression with doxycycline after differentiation to knockout certain genes of interest. Maintain brown pre-adipocytes and white pre-adipocytes in DMEM supplemented with 20% FBS at 37°C and 5% CO2. Passage the cells at 1:6 or more every 2 days. Plates can be pre-coated with 0.1% gelatin to prevent cell detachment. The volume of 0.1% gelatin added is as follows: 12-well plate, 1 mL/well, 6-well plate, 1.5 mL/well, and 10-cm culture dish, 6 mL/dish. Plate pre-adipocytes in 6-well plates for lentiviral infection. After approximately 8 h, add lentiviruses (carry sgRNA) to cells (day 1). Add ∼6 × 105 viral particles to 2 × 105 cells, which typically resulted in 20%–30% of cells infected (Figure 1A).
Figure 1

Lentiviral infection and puromycin treatment

Representative images show the density variation of brown pre-adipocytes after lentiviral infection from day 1 to day 3 (A); or after puromycin treatment from day 4 to day 6 (B). The lentiCRISPRv2 vector contains the puromycin cassette while the lenti-GFP vector does not. Thus, cells infected with lentiCRISPRv2 viruses are resistant to puromycin treatment, and cells infected with lenti-GFP viruses are puromycin-irresistant. Scale bar, 200 μm.

CRITICAL: It is recommended to set up control groups (cells infected with lentiviruses that carry no sgRNA or express GFP). Polybrene (8 μg/mL) can be added to increase transduction efficiency. Lentiviral infection and puromycin treatment Representative images show the density variation of brown pre-adipocytes after lentiviral infection from day 1 to day 3 (A); or after puromycin treatment from day 4 to day 6 (B). The lentiCRISPRv2 vector contains the puromycin cassette while the lenti-GFP vector does not. Thus, cells infected with lentiCRISPRv2 viruses are resistant to puromycin treatment, and cells infected with lenti-GFP viruses are puromycin-irresistant. Scale bar, 200 μm. After 48 h of transduction, treat cells with 1.5 μg/μL puromycin for 2 days to remove non-infected cells (Figure 1B). After 2 days of puromycin treatment, collect cells and plate cells in a new 12-well plate for differentiation. Troubleshooting 2 (The number of infected pre-adipocytes might be variable, thereby resulting in experimental variability) It is recommended to allow these infected cells to grow in growth medium for one more day before differentiation. Adipocyte differentiation. The protocol for the differentiation of white pre-adipocytes is similar to that for the differentiation of brown pre-adipocytes, with the exception that no T3 and 5 μg/mL insulin is used during the whole differentiation process (Qiu et al., 2018, Feng et al., 2019). Thus, this protocol mainly describes the brown pre-adipocytes differentiation. CRITICAL: Prepare all reagents for adipocyte differentiation before use. Aliquot stock solutions into small volumes. Avoid repeatedly freezing and thawing. When brown pre-adipocytes grow confluent (termed “day 0”), remove the growth medium and add induction medium to induce adipogenesis. The induction medium should be freshly prepared before use. On day 3, remove the induction medium and add the maintenance medium. Do not wash cells with PBS. The maintenance medium should be freshly prepared before use. Change the maintenance medium every 2 days. On day 6 or 7, Typically more than 90% of cells are differentiated. Troubleshooting 3 (Low differentiation potential of pre-adipocytes) Change the maintenance medium daily if it appears yellow.

Functional validation of sgRNAs

Timing: 1–2 days Functional testing for the detection of indel mutations by surveyor assay (Timing: 1 day): Confirm the function of sgRNA in adipocytes by detecting the indel mutations generated by specific sgRNAs. The protocol is identical to that in step 7. Troubleshooting 4 (No obvious cleavage bands after T7 endonuclease I digestion) Functional testing to determine protein expression Timing: 2 days Collect the well-differentiated adipocytes in 1.5 mL tube. For one well of 12-well plate, add 60 μL RIPA buffer into the tube, mix gently by pipetting up and down for a few times, and put the mixture on ice for 15 min. The volume of RIPA buffer can be flexible. For one well of 12-well plate, it is recommended to add 60 μL RIPA buffer to lysis cells. Centrifuge 15 min at 15,294 × g, and transfer the lysis buffer (middle layer) to a new 1.5 mL tube (Figure 2).
Figure 2

Schematic view of the layers after centrifugation (step 12b)

The upper layer is lipid, the middle layer is the lysis buffer, and the lower layer is the cell debris.

This step can be repeated to remove lipids. Troubleshooting 5 (Lipid droplets in mature adipocytes reduce protein extraction efficiency) Schematic view of the layers after centrifugation (step 12b) The upper layer is lipid, the middle layer is the lysis buffer, and the lower layer is the cell debris. Add 3× SDS-PAGE loading buffer to each tube, and incubate the mixture at 95°C for 5 min. The volume of 3× SDS-PAGE loading buffer depends on the volume of RIPA buffer in step 12a. For 60 μL RIPA buffer, add 30 μL 3× SDS-PAGE loading buffer. Place the solution on ice for immediate use or store the solution at −20°C or −80°C for future use. Run the protein samples on a SDS-PAGE gel, and detect the target protein expression using corresponding antibodies.

Expected outcomes

When running the DNA samples on 1% (wt/vol) agarose gel, high-efficiency sgRNA will generate obvious cleavage bands, whereas the negative controls will have no cleavage bands (Figure 3). When running protein samples on SDS-PAGE gel, high-efficiency sgRNA will result in significantly decreased target protein expression.
Figure 3

Surveyor assay and western blot results illustrating the editing activity of selected sgRNAs

(A) Assessment of sgRNA cleavage efficiency by surveyor assay. sgRNA that results in obvious cleavage bands indicates high-efficiency sgRNA, such as sgRNA1 and 2 showed here. sgRNA that hardly generates any cleavage bands indicate low-efficiency sgRNA, such as sgRNA3 showed here. The sgRNA efficiency is quantified by ImageJ. (B) Western blot confirming the reduction in protein levels resulted by selected sgRNA. Figure reprinted with permission from Qiu et al. (2020).

Surveyor assay and western blot results illustrating the editing activity of selected sgRNAs (A) Assessment of sgRNA cleavage efficiency by surveyor assay. sgRNA that results in obvious cleavage bands indicates high-efficiency sgRNA, such as sgRNA1 and 2 showed here. sgRNA that hardly generates any cleavage bands indicate low-efficiency sgRNA, such as sgRNA3 showed here. The sgRNA efficiency is quantified by ImageJ. (B) Western blot confirming the reduction in protein levels resulted by selected sgRNA. Figure reprinted with permission from Qiu et al. (2020).

Limitations

In this protocol, as gene editing is performed in a group of cells, it usually results in a knockdown effect, as in some cells with a certain percentage, CRISPR editing results in indels with multiples of 3 nt, thus resulting in deletion or insertion of several amino acids, but not frameshift or early protein truncation. In order to ensure a knockout effect, single clones must be isolated with sequencing confirmed with a frameshift indel mutation. Another limitation of this protocol is that genes are edited in pre-adipocytes but not directly in mature adipocytes. It is possible that knockout of certain gene may have functional consequences to adipocyte differentiation. If researchers want to exclude possible effect of a gene during adipocyte differentiation, we recommend using inducible CRISPR/Cas9 system, for example, the pCW-Cas9 (Addgene, #50661), to start gene editing after adipocyte differentiation in mature adipocytes. This works by infecting pre-adipocytes with the inducible CRISPR/Cas9 system to introduce the Cas9 and sgRNA cassettes to cells, and induce the Cas9 expression with doxycycline after differentiation to knockout certain genes of interest.

Troubleshooting

Problem 1

Low titers of lentiviruses (step 4).

Potential solution

This might occur due to multiple reasons: first, poor HEK293T cell health. It is recommended to use low-passage cells. We usually discard cells that have been passaged for more than 15 times. Second, low transfection efficiency of plasmids. Check the quality of transfection reagents or change to other more-efficient transfection reagents. Improper cell density (too low or too high) also results in low transfection efficiency. Third, the time for transfection. According to our experience, transfect plasmids 16–24 h after seeding will improve lentiviruses titers.

Problem 2

The number of infected pre-adipocytes might be variable (step 9d), thereby resulting in experimental variability. This might occur due to multiple reasons. The viral titer might not be accurate. Therefore, titer the lentiviral samples with a commercial qPCR Lentivirus Titration Kit before use. If the target gene affects cell growth, the density of pre-adipocytes for different groups may be different. To determine this, seed the same number of cells for different groups in a 12-well plate to induce differentiation. The concentration of puromycin might be different in each sample. To avoid this, prepare a puromycin stock solution and then make diluted samples to ensure homogeneity. Avoid addition of puromycin individually.

Problem 3

Low differentiation potential of pre-adipocytes (step 10). This might occur due to multiple reasons. First, poor cell health can alter growth rate or morphology. Cells that have more than 15 passages should not be used. A higher number of cell divisions might decrease the differentiation capacity. Second, the activity of compounds used for differentiation is low. Aliquot to avoid repeated freezing and thawing. Third, improper cell density. Cell density in a too low or too high level may affect differentiation.

Problem 4

No obvious cleavage bands after T7 endonuclease I digestion (step 7g and step 11). This might occur due to low editing activity of sgRNA. Therefore, it is recommended to design at least three sgRNAs and screen for sgRNAs with high editing activity. The sgRNA with the highest editing activity should be selected to transfect cells. Second, low activity of T7EI can cause incomplete digestion. The editing activity of sgRNA can also be determined by sequencing the PCR product generated using surveyor primers. Third, the time required for T7EI digestion might be short. Therefore, the PCR products can be incubated with T7EI enzyme for a longer duration to achieve complete digestion.

Problem 5

Lipid droplets in mature adipocytes reduce protein extraction efficiency (step 12b). The lipid droplet content is positively correlated with the maturity of adipocytes. Remove the lipid droplets after addition of RIPA buffer to cells. Moreover, it is recommended to repeat this step until no obvious lipid droplets are observed.

Resource availability

Lead contact

Further information and requests for resources should be directed to and will be fulfilled by the Lead Contact, Dr. Qiurong Ding (qrding@sibs.ac.cn).

Materials availability

All unique materials generated from this study are available from the Lead Contact with a complete Materials Transfer Agreement.

Data and code availability

We did not generate any unique datasets or data.
REAGENT or RESOURCESOURCEIDENTIFIER
Recombinant DNA

lentiCRISPRv2AddgeneCat# 52961
pMDLg/pRREAddgeneCat# 12251
pRSV-RevAddgeneCat# 12253
pMD2.GAddgeneCat# 12259
pUC57-MU6-gRNAGenewizn/a
pCW-Cas9AddgeneCat# 50661

Chemicals, peptides, and recombinant proteins

T7 Endonuclease INEBCat# M0302L
BsmBINEBCat# R0580
NEbuffer 3.1NEBn/a
NEbuffer 2NEBn/a
BbsI-HFNEBCat# R3539S
CutSmartNEBn/a
EcoRINEBCat# R3101S
KOD bufferTOYOBOCat# KOD-401
Ligation highTOYOBOCat# LGK-101
2× Taq Master Mix (Dye)TransGen BiotechCat# CW0682
Polyethylenimine (PEI)PolysciencesCat# 23966-1
PolybreneMerckCat# TR-1003-50UL
GelatinSanta CruzCat# sc-218567
InsulinSanta CruzCat# sc-29062
T3SigmaCat# T-2877
IndomethacinSigmaCat# I-7378
DexamethasoneSigmaCat# D-4902
IBMXSigmaCat# I-5879
RosiglitazoneSanta CruzCat# sc-20279
DMEMGibcoCat# 8117254
FBSGibcoCat# 16000044
Puromycin dihydrochlorideBioVisionCat# 295160
RIPA bufferMilliporeCat# 20188
SDS-PAGE gelEpizymeCat# PG112
AmpicillinBeyotime BiotechnologyCat# ST007
DTTSangon BiotechCat# A100281-0005
Tris-HClSinopharm Chemical ReagentCat# 73509461
SDSAmrescoCat# 0227-1KG
GlycerolSinopharm Chemical ReagentCat# 10010618
Bromophenol blueSangon BiotechCat# A500922-0025
AgaroseBiowestCat# BY-R0100
Yeast extractOXOIDCat# LP0021
TryptoneOXOIDCat# LP0042
NaClSangon BiotechCat# 7647-14-5
Agar powderSolarbioCat# A8190
Calcium chloride dihydrateSigmaCat# C7902

Critical commercial assays

TIANprep Mini Plasmid KitTIANGENCat# DP103
TIANamp Genomic DNA KitTIANGENCat# DP304-03
Gel Extraction KitCWBIOCat# CW2302M
qPCR Lentivirus Titration KitAbmCat# LV900

Experimental models: cell lines

HEK293TCell Bank, Type Culture Collection Committee, Chinese Academy of Sciencesn/a
NIH3T3Cell Bank, Type Culture Collection Committee, Chinese Academy of Sciencesn/a
Brown adipocytesn/an/a
White adipocytesn/an/a

Other

0.22-μm vacuum filterMilliporeCat# SLGP033RB
0.45-μm vacuum filterMilliporeCat# SLHV033RB
Beckman JA25.50 rotorBeckmann/a

Bacterial and virus strains

Trans5α Chemically Competent CellTransGenCat# 431675
NEB Stable competent cellNEBCat# C3040I
One Shot StbI3 chemically competent cellInvitrogenCat# C737303

Oligonucleotides

sgRNA forward: 5′-CACCGNNNNNNNNNNNNNNNNNNNN-3′n/an/a
sgRNA reverse: 5′-AAACNNNNNNNNNNNNNNNNNNNNC-3′n/an/a
ReagentStock concentrationFinal concentrationVolume to add
DMEMn/an/a45 mL
10% FBSn/an/a5 mL
Insulin5 mg/mL1 μg/mL10 μL
T310 μM1 nM5 μL
Indomethacin0.125 M0.125 mM50 μL
Dexamethasone1 mM1 μM50 μL
IBMX0.5 M0.5 mM50 μL
Rosiglitazone1 mM1 μM50 μL
Totaln/an/a50 mL
ReagentStock concentrationFinal concentrationVolume to add
DMEMn/an/a45 mL
10% FBSn/an/a5 mL
Insulin5 mg/mL1 μg/mL10 μL
T310 μM1 nM5 μL
Totaln/an/a50 mL
ReagentAmount
Yeast extract5 g
Tryptone10 g
NaCl10 g
ddH2Oto 1 L
Total1 L
ReagentAmount
1 M Tris-HCl (pH 6.8)7.5 mL
DTT2.313 g
SDS3 g
Glycerol15 mL
Bromophenol blue0.015 g
ddH2Oto 50 mL
Total50 mL
ComponentAmount (μL)
sgRNA-F (10 μM)1
sgRNA-R (10 μM)1
KOD buffer (10×)10
ddH2O88
Total100
ComponentAmount
lentiCRISPRv21 μg
BsmBI0.5 μL
NEbuffer3.1 (10×)2 μL
ddH2Oto 20 μL
Total20 μL
ComponentAmount (μL)
BsmBI-digested lentiCRISPRv2 from step 20.3
sgRNA from step 15.7
Ligation high3
Total9 μL
ComponentAmount (μg)
pMDLg/pRRE7.35
pMD2.G3.95
pRSV-Rev2.85
lentiCRISPR-sgRNA11.25
Total25.4
ComponentAmount
Surveyor-F (10 μM)1 μL
Surveyor-R (10 μM)1 μL
2× Taq50 μL
Genomic DNA500 ng
ddH2Oto 100 μL
Total100 μL
PCR cycling conditions
StepsTemperatureTimeCycles
Initial denaturation94°C2 min1
Denaturation94°C30 s25–35 cycles
Annealing58°C30 s
Extension72°C15 s
Final extension72°C5 min1
Hold4°Cforever
ComponentAmount
DNA product from step 7c250 ng
NEbuffer 2 (10×)2 μL
ddH2Oto 20 μL
Total20 μL
ComponentAmount
pUC57-MU6-gRNA1 μg
BbsI-HF0.5 μL
CutSmart (10×)2 μL
ddH2Oto 20 μL
Total20 μL
ComponentAmount (μL)
lentiCRISPR-sgRNA1 from step 8d0.3
Mouse U6-sgRNA2 fragment from step 8c5.7
Ligation high3
Total9 μL
  9 in total

1.  Production and purification of lentiviral vectors.

Authors:  Gustavo Tiscornia; Oded Singer; Inder M Verma
Journal:  Nat Protoc       Date:  2006       Impact factor: 13.491

2.  Genome engineering using the CRISPR-Cas9 system.

Authors:  F Ann Ran; Patrick D Hsu; Jason Wright; Vineeta Agarwala; David A Scott; Feng Zhang
Journal:  Nat Protoc       Date:  2013-10-24       Impact factor: 13.491

3.  Production of High-Titer Lentiviral Particles for Stable Genetic Modification of Mammalian Cells.

Authors:  Michael R Larcombe; Jan Manent; Joseph Chen; Ketan Mishra; Xiaodong Liu; Christian M Nefzger
Journal:  Methods Mol Biol       Date:  2019

4.  A third-generation lentivirus vector with a conditional packaging system.

Authors:  T Dull; R Zufferey; M Kelly; R J Mandel; M Nguyen; D Trono; L Naldini
Journal:  J Virol       Date:  1998-11       Impact factor: 5.103

5.  Optimized sgRNA design to maximize activity and minimize off-target effects of CRISPR-Cas9.

Authors:  John G Doench; Nicolo Fusi; Meagan Sullender; Mudra Hegde; Emma W Vaimberg; Jennifer Listgarten; Katherine F Donovan; Ian Smith; Zuzana Tothova; Craig Wilen; Robert Orchard; Herbert W Virgin; David E Root
Journal:  Nat Biotechnol       Date:  2016-01-18       Impact factor: 54.908

6.  Glyburide Regulates UCP1 Expression in Adipocytes Independent of KATP Channel Blockade.

Authors:  Yan Qiu; Yuanyuan Yang; Yuda Wei; Xiaojian Liu; Zhuanghui Feng; Xuwen Zeng; Yanhao Chen; Yan Liu; Yongxu Zhao; Lanlan Chen; Lijun Luo; Qiurong Ding
Journal:  iScience       Date:  2020-08-10

7.  Optimized libraries for CRISPR-Cas9 genetic screens with multiple modalities.

Authors:  Kendall R Sanson; Ruth E Hanna; Mudra Hegde; Katherine F Donovan; Christine Strand; Meagan E Sullender; Emma W Vaimberg; Amy Goodale; David E Root; Federica Piccioni; John G Doench
Journal:  Nat Commun       Date:  2018-12-21       Impact factor: 14.919

8.  Identification of a rhodanine derivative BML-260 as a potent stimulator of UCP1 expression.

Authors:  Zhuanghui Feng; Yuda Wei; Yongxian Zhang; Yan Qiu; Xiaojian Liu; Li Su; Ningning Liang; Huiyong Yin; Qiurong Ding
Journal:  Theranostics       Date:  2019-05-26       Impact factor: 11.556

9.  Screening of FDA-approved drugs identifies sutent as a modulator of UCP1 expression in brown adipose tissue.

Authors:  Yan Qiu; Yingmin Sun; Danqing Xu; Yuanyuan Yang; Xiaojian Liu; Yuda Wei; Yanhao Chen; Zhuanghui Feng; Shuang Li; Md Reyad-Ul Ferdous; Yongxu Zhao; Hongxi Xu; Yuanzhi Lao; Qiurong Ding
Journal:  EBioMedicine       Date:  2018-10-20       Impact factor: 8.143

  9 in total
  2 in total

1.  Optimized protocols for efficient gene editing in mouse hepatocytes in vivo using CRISPR-Cas9 technology.

Authors:  Yanhao Chen; Qiurong Ding
Journal:  STAR Protoc       Date:  2021-12-23

2.  A proteomics protocol to identify stimulation-induced binding partners dependent on a specific gene in mammalian cells.

Authors:  Junji Zhu; Wuhan Xiao
Journal:  STAR Protoc       Date:  2021-11-13
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.